Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Down 35.2% in December

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 23,700 shares, a drop of 35.2% from the December 15th total of 36,600 shares. Based on an average daily volume of 43,400 shares, the short-interest ratio is currently 0.5 days. Approximately 0.7% of the company’s shares are sold short.

Institutional Investors Weigh In On Lakeshore Biopharma

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC purchased a new position in shares of Lakeshore Biopharma in the 3rd quarter worth about $803,000. Hhlr Advisors LTD. acquired a new stake in Lakeshore Biopharma during the 3rd quarter worth approximately $513,000. Finally, Barclays PLC purchased a new position in Lakeshore Biopharma in the third quarter valued at approximately $169,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Price Performance

Shares of NASDAQ LSB opened at $2.86 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.13 and a quick ratio of 0.87. The company’s fifty day moving average is $2.85. Lakeshore Biopharma has a 52-week low of $1.88 and a 52-week high of $11.20.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.